Prescriber Resources

POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Enrolling in POMALYST REMS®

In order to prescribe POMALYST, you must enroll in the POMALYST REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to Celgene Customer Care at 1-888-432-9325.

Prescribing POMALYST for your patients

In order to receive POMALYST, your patients must also be enrolled in the POMALYST REMS® program. You can enroll your patients, and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.

Additionally, you can also enroll your patients and write prescriptions by downloading the Desktop Software and installing it on your computer.

Learning more about POMALYST REMS®

For additional information about the POMALYST REMS® program process, please see the educational materials below.


Please report adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST to Celgene using any of the following methods:

REPORTING TO CELGENE

Email:

Telephone:

1-908-673-9667

Toll-free:

1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Celgene Customer Care Center)

Fax:

1-908-673-9115

Mail to:

Global Drug Safety & Risk Management
Celgene Corporation
556 Morris Avenue
Building S12
Summit, New Jersey 07901

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST may also be reported to the FDA MedWatch Reporting System using any of the following methods:

Online:

Telephone:

1-800-FDA-1088

Fax:

1-800-FDA-0178

Mail to:

MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: